Seoul Economic Daily EnglishCodex · 实盘不做把握 4/10
北京时间·🕒 发布 08:35:57(首尔 09:35)·⟳ 抓取 08:48:38 +12m41s·⚡ 决策 08-18 08:52:00 +3m22s·70.3 天前
JW Pharmaceutical提交Bofanglutide韩国肥胖症III期临床IND申请
IND提交是JW Pharmaceutical（001060.KS）韩国商业化路径的推进，但距离启动试验和上市仍有多年，短线收入增量为零。
📄 原文Seoul Economic Daily English↗ 原文
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug in Korea
JW Pharmaceutical is launching a domestic Phase 3 trial of Bofanglutide, an obesity treatment given once every two week…
不做 JW Pharmaceutical（001060.KS）
本次IND提交方向偏正面但属于4月授权后预期内进展，距离商业化和业绩兑现太远，且缺少真实行情和先例校准，不形成可执行短线edge。
不做 甘李药业（603087.SH）
韩国IND推进对原研方偏利好但未披露新增里程碑收款或商业化收入，且对A股甘李药业短线业绩量级无法确认，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 媒体报道JW Pharmaceutical已提交Bofanglutide韩国肥胖症III期IND申请，为本次具体催化的最早可见英文传播节点。
- 公司此前已披露从Gan & Lee取得韩国独家权益、总潜在交易额8110万美元及后续IND/NDA合作安排，说明本次IND提交是旧授权后的进展。
关键理由
- IND提交是JW Pharmaceutical（001060.KS）韩国商业化路径的推进，但距离启动试验和上市仍有多年，短线收入增量为零。
- Bofanglutide韩国权益早在2026年4月授权交易中已公开，金额、适应症和韩国III期计划均已被市场提前知道，本次更多是执行进展。
- 量级上，韩国GLP-1RA市场2025年约5.26亿美元、2033年预期约16亿美元，但JW仅拥有韩国权益且需III期成功和获批后才可能兑现，当前无法转化为1-10日业绩增量。
主要风险
- IND仍需MFDS批准，且计划2029年才完成主要评估，临床失败、审批延迟和商业化竞争会削弱价值。
- 未能取得实时行情和内部案例/事件研究工具结果，因此不满足ENTER所需的真实报价和先例定价校准。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-04-09 · 影响 weakens
4月授权公告已明确韩国开发、注册和商业化权益及后续IND/NDA支持，本次属于预期内研发推进。
检索:JW Pharmaceutical Bofanglutide IND Phase 3 already planned April 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-18 · 影响 weakens
试验计划至2029年3月评估疗效和安全性，短线没有销售、利润或里程碑确认。
检索:Bofanglutide Korea Phase 3 trial timeline March 2029 commercialization risk 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加事件已在4月授权时预告，最终降低置信度并不下单。
方向:未能取得可量化的同市场同相位先例；从事件性质看，药物IND提交通常只代表研发进展，不等于商业化获批。
涨幅量级:缺少event_study结果，不能用先例校准短线涨幅。
形态:未发现足够样本证明韩国药企单一IND提交在1-5日窗口有稳定正收益。
原文全文
展开原文 · 2,193 字
JW Pharmaceutical is launching a domestic Phase 3 trial of Bofanglutide, an obesity treatment given once every two weeks. The drug halves the number of doses compared with existing once-weekly glucagon-like peptide-1 (GLP-1) treatments, aiming to improve patient convenience.
The company said on the 18th that it had filed an investigational new drug (IND) application for the Phase 3 trial with the Ministry of Food and Drug Safety. The multicenter, placebo-controlled Phase 3 trial will enroll 300 domestic adults with obesity or overweight. Pending approval from the ministry, the company plans to begin the trial in December and to evaluate weight-loss efficacy and safety against placebo through March 2029.
Bofanglutide is a GLP-1 receptor agonist for which JW Pharmaceutical secured exclusive domestic development and commercialization rights in April from China's Gan & Lee Pharmaceuticals. It acts on GLP-1 receptors in the pancreas to stimulate insulin secretion and slows the emptying of food from the stomach to increase satiety, thereby suppressing appetite and driving weight loss.
Unlike the once-weekly GLP-1 obesity treatments now in wide use, it is being developed as a subcutaneous (SC) injection given once every two weeks. Cutting the annual number of doses from 52 to 26 is expected to improve convenience and medication adherence.
According to earlier Phase 3 results in China, Bofanglutide reduced body weight from baseline by 15.12% in the 24-mg dose group and by 18.54% in the 48-mg dose group after 52 weeks of treatment. JW Pharmaceutical said it plans to verify in Korean patients the efficacy and tolerability confirmed in the overseas trial.
The company also plans to pursue Phase 3 trials for additional indications of Bofanglutide in sequence, starting with obesity, to expand its portfolio of original prescription drugs in the metabolic disease field.
A JW Pharmaceutical official stressed, "We will clearly demonstrate in Korean patients the weight-loss effect and tolerability confirmed in overseas trials," adding, "We will accelerate development so that we can offer a new obesity treatment option that combines clinical efficacy and dosing convenience."
The company said on the 18th that it had filed an investigational new drug (IND) application for the Phase 3 trial with the Ministry of Food and Drug Safety. The multicenter, placebo-controlled Phase 3 trial will enroll 300 domestic adults with obesity or overweight. Pending approval from the ministry, the company plans to begin the trial in December and to evaluate weight-loss efficacy and safety against placebo through March 2029.
Bofanglutide is a GLP-1 receptor agonist for which JW Pharmaceutical secured exclusive domestic development and commercialization rights in April from China's Gan & Lee Pharmaceuticals. It acts on GLP-1 receptors in the pancreas to stimulate insulin secretion and slows the emptying of food from the stomach to increase satiety, thereby suppressing appetite and driving weight loss.
Unlike the once-weekly GLP-1 obesity treatments now in wide use, it is being developed as a subcutaneous (SC) injection given once every two weeks. Cutting the annual number of doses from 52 to 26 is expected to improve convenience and medication adherence.
According to earlier Phase 3 results in China, Bofanglutide reduced body weight from baseline by 15.12% in the 24-mg dose group and by 18.54% in the 48-mg dose group after 52 weeks of treatment. JW Pharmaceutical said it plans to verify in Korean patients the efficacy and tolerability confirmed in the overseas trial.
The company also plans to pursue Phase 3 trials for additional indications of Bofanglutide in sequence, starting with obesity, to expand its portfolio of original prescription drugs in the metabolic disease field.
A JW Pharmaceutical official stressed, "We will clearly demonstrate in Korean patients the weight-loss effect and tolerability confirmed in overseas trials," adding, "We will accelerate development so that we can offer a new obesity treatment option that combines clinical efficacy and dosing convenience."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。